Most Read Articles
Naomi Rodrig, 27 Apr 2016

LUX-Lung 7, a global phase IIb, randomized, open-label trial, demonstrated significant improvements in progression-free survival (PFS), time to treatment failure (TTF) and objective response rate (ORR) with afatinib vs gefitinib as first-line treatment for patients with advanced, EGFR-positive non-small-cell lung cancer (NSCLC). [ELCC 2016, abstract 140PD]

Naomi Rodrig, 28 Apr 2016
A combination of live-bacterium immunotherapy and standard chemotherapy is safe and effective in patients with malignant pleural mesothelioma (MPM), providing a response rate of nearly 60 percent, according to a recent phase Ib trial. [ELCC 2016, abstract 208O_PR]
Pearl Toh, 13 May 2017
Short-term use of oral corticosteroids was associated with increased risks of adverse events such as fracture, sepsis, and venous thromboembolism (VTE), a large US cohort study showed.
Naomi Rodrig, 03 May 2016
Third-generation EGFR tyrosine kinase inhibitors (TKIs) designed to overcome the T790M mutation have been shown to double progression-free survival (PFS) of patients with advanced non-small-cell lung cancer (NSCLC) harbouring activating EGFR mutations, according to reports at the European Lung Cancer Conference (ELCC) 2016 held recently in Geneva, Switzerland.

Adjuvant chemotherapy, cardiac disease history predict PCE after radiation for NSCLC

10 Sep 2017
Lack of public awareness about the way lung cancer strikes is a big factor in delaying diagnosis and treatment

Pericardial effusion (PCE) is a common adverse side effect following thoracic radiation therapy (RT) for locally-advanced nonsmall cell lung cancer (NSCLC), a new study reveals. Additionally, PCE risk is increased by adjuvant chemotherapy.

The effects of intensity-modulated radiation therapy (IMRT) vs passive scattering proton beam therapy for locally advanced, inoperable NSCLC were assessed in 201 patients (56.2 percent male). Those with chest irradiation or PCE prior to treatment were excluded.

The primary study endpoint was development of PCE. Other outcomes included time to development – calculated from the start of RT – and overall survival (OS). Univariate and Multivariate Cox proportional hazards analyses were used to determine hazard ratios (HR) for PCE development.

Over a median follow-up of 23.9 months, participants received a median RT dose of 74 Gy and heart dose of 12.2 Gy. PCE was reported in 42.8 percent (n=86) of the patients, of which 40.3 percent (n=81) had grade 2 and 5.2 percent (n=5) had grade 3 PCE.

The 1- and 2-year cumulative PCE incidence rates were 31.4 and 45.4 percent, respectively, with a median time to development of 8.9 months.

The OS at 2 years was significantly higher in the PCE group than in those without PCE (69.0 vs 44.3 percent; p=0.012); at 5 years, the difference in corresponding OS rates decreased (43.3 vs 25.6 percent).

In multivariate analysis, heart volume receiving 35 Gy >10 percent (HR, 2.14; p=0.002), adjuvant chemotherapy (HR, 2.82; p<0.001) and history of cardiac disease (HR, 1.68; p=0.020) were all independent risk predictors for PCE.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Naomi Rodrig, 27 Apr 2016

LUX-Lung 7, a global phase IIb, randomized, open-label trial, demonstrated significant improvements in progression-free survival (PFS), time to treatment failure (TTF) and objective response rate (ORR) with afatinib vs gefitinib as first-line treatment for patients with advanced, EGFR-positive non-small-cell lung cancer (NSCLC). [ELCC 2016, abstract 140PD]

Naomi Rodrig, 28 Apr 2016
A combination of live-bacterium immunotherapy and standard chemotherapy is safe and effective in patients with malignant pleural mesothelioma (MPM), providing a response rate of nearly 60 percent, according to a recent phase Ib trial. [ELCC 2016, abstract 208O_PR]
Pearl Toh, 13 May 2017
Short-term use of oral corticosteroids was associated with increased risks of adverse events such as fracture, sepsis, and venous thromboembolism (VTE), a large US cohort study showed.
Naomi Rodrig, 03 May 2016
Third-generation EGFR tyrosine kinase inhibitors (TKIs) designed to overcome the T790M mutation have been shown to double progression-free survival (PFS) of patients with advanced non-small-cell lung cancer (NSCLC) harbouring activating EGFR mutations, according to reports at the European Lung Cancer Conference (ELCC) 2016 held recently in Geneva, Switzerland.